Navigation Links
VIIa in Medical News

Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products

Multi-Product Collaboration Valued Potentially at More Than $500 Million COLLEGEVILLE, Pa., and SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ) and Catalyst Biosciences, Inc. today announced that the two companies have formed an e...

FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors

First Recombinant Room Temperature Stable Treatment for Hemophilia With Inhibitors Offers More Flexibility and Convenience to Patients PRINCETON, N.J., May 13 /PRNewswire-FirstCall/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved NovoSeven(R) RT ...

Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results

...ily due to reduced personnel expenses, reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, Btk and Factor viia Inhibitor programs. Pharmacyclics also reported its financial results for the nine months ended March 31, 2009. The net loss for the nine months...

Bayer HealthCare Marks 20th Anniversary of World Hemophilia Day With Euro 250,000 Contribution to the World Federation of Hemophilia

...mophilia A. Bayer is currently the only company with such a product in human clinical trials. Developing a next-generation recombinant factor viia protein that may provide additional treatment options to patients with hemophilia, who have developed antibodies - or inhibitors - to either factor VI...

Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer

...l development. His expertise in clinical development and operations is particularly welcome as we advance our lead program, CB 813, an improved factor viia product for the treatment of acute bleeding in hemophiliacs, toward an IND filing in 2009." "I am delighted to join Catalyst and have the opportunit...

Pharmaceutical study: Less hemorrhaging after stroke, but not fewer deaths

...of Medicine has shown that the coagulation factor viia can limit the extent of a cerebral hemorrhage. How... phase-2 study with recombinant coagulation factor viia with the trade name NovoSeven, which is not yet ap...The new study compares the effectiveness of factor viia in two dosages (20 and 80 micrograms) with a place...

Pharmacyclics Reports Third Quarter 2008 Financial Results

...associated with the Company's HDAC, Btk and Factor viia inhibitor programs. Pharmacyclics also reported ...vestigational new drug applications for our Factor viia inhibitor and our Btk inhibitor," said Richard A. ...esentations relating to the company's HDAC, Factor viia and Btk programs were made at the American Ass...

JCI online early table of contents: April 8, 2008

...View the PDF of this article at: https://www.the-jci.org/article.php?id=33680 HEMATOLOGY Too much of a good thing: high levels of factor viia cause problems in mice Individuals with hemophilia lack either factor VIII or factor IX, proteins crucial for the cascade of events that leads to ...

Maxygen to Host Fourth Quarter and Year End 2007 Financial Results Conference Call on February 12, 2008

... improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in our pipeline is a novel Factor viia for the treatment of hemophilia. Maxygen's approach to drug discovery and development may allow us to leverage the established development and regulat...
VIIa in Medical Technology

Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483

SUNNYVALE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced that the company has completed a Phase 1 clinical trial with PCI-27483, the company's novel, first-in-class small-molecule Factor VIIa inhibitor. The trial was conducted in sixteen (16) healt...

Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, announced that it has selected CB 813, an improved, second-generation variant of human coagulation factor VIIa, ...

Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer

SAN DIEGO and SUNNYVALE, Calif., April 16 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today presented preclinical results demonstrating the anti-tumor activity of PCI-27483, the company's small-molecule Factor VIIa inhibitor. The data were presented during the Annual Meeting...

Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

HORSHAM, Pa.--(BUSINESS WIRE)--Jul 11, 2007 - Neose Technologies, Inc. (Nasdaq GM:NTEC) today announced that two poster presentations were presented with its collaborative partner, Novo Nordisk A/S, relating to GlycoPEGylated recombinant Factor VIIa at the XXIst Congress of the International Societ...

Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.

...se III clinical development for cancer. This includes a leading histone deacetylase inhibitor (PCI-24781) for multiple cancers; an inhibitor of Factor viia (PCI-27483) targeting pancreatic, gastric, colon and breast cancers; a first in class inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765) currentl...

Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG-GCSF

... improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in our pipeline is a novel Factor viia for the treatment of hemophilia. Maxygen's approach to drug discovery and development may allow us to leverage the established development and regulat...

CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity

...tudy that show for the first time it is feasible to genetically fuse Factor viia (FVIIa) to human albumin, prolonging the half- life of this therapeutic pro...ed a biologic activity comparable to wild type rFVIIa. Recombinant factor viia (rFVIIa) may be used to control bleeding episodes in hemophilia patients wi...

Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session

...bstract Title: Safety and Tolerability of a Novel Tissue Factor/Factor viia Inhibitor rNAPc2 in Patients With Non-ST-Elevation Acute Coronary Synd...nalysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor viia and tissue factor protease complex that completed Phase 2 clinical developm...

Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting

...ent of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor viia and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct ...

Nuvelo Announces Publication of NU206 Study Results in Gastroenterology

...ent of thrombotic-related disorders which is suspended pending review and analysis of clinical data; rNAPc2, an anticoagulant that inhibits the factor viia and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct ...
VIIa in Biological News

UI researcher studies deafness in fruit flies, humans

... deafness in humans. Their research paper, "Myosin viia Defects, which Underlie the Usher 1B Syndrome in H...ork -- showing that loss of function in the Myosin viia gene leads to complete deafness in fruit flies -- ...r abnormalities and deafness in humans. "Myosin viia was one of the first human hereditary deafness gen...
VIIa in Biological Technology

Pharmacyclics, Inc. Rights Offering Oversubscribed

...ent of today's offering, we have the capital to drive our programs forward, particularly PCI 32765, our novel BTK Inhibitor, and PCI 24783, our Factor viia Inhibitor, to several inflection points. We are committed to driving shareholder value and look forward to updating you on our progress as we continue...

Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results

...ical expenses associated with the company's Factor viia inhibitor program due to the completion of preclin... lymphomas and the filing of an IND for our Factor viia inhibitor," said Richard A. Miller, M.D., presiden...27483, a small molecule inhibitor of Factor viia being developed both for the treatment of t...

Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting

...ler, M.D., president and chief executive officer of Pharmacyclics. "In addition to data on our HDAC inhibitor, other presentations describe our Factor viia and Btk inhibitors, which we anticipate will enter clinical testing later this year." About Pharmacyclics Pharmacyclics is a pharmaceutical compan...

Monogram HIV Antibody Assay Is Key Component of Innovative Vaccine Development Program

... of long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen's pipeline are a new Factor viia product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its prop...

Maxygen to Present at the Cowen & Company 28th Annual Health Care Conference

...n of long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen's pipeline is a new Factor viia product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its prop...

Maxygen Announces Management Changes

... of long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen's pipeline are a new Factor viia product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its prop...

Maxygen Reports Fourth Quarter and Year End 2007 Financial Results

...oss of revenues from Maxygen's collaboration with Roche to develop a Factor viia for acute bleeding conditions. That collaboration ended in the second quart...tly in Phase II clinical trials. Also in Maxygen's pipeline is a new Factor viia product candidate for the treatment of hemophilia and new CTLA4-Ig product ...

Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference

...ed version of PEG-GCSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen's pipeline is a new Factor viia product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its prop...

Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference

... improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in our pipeline is a novel Factor viia for the treatment of hemophilia. Maxygen's approach to drug discovery and development may allow us to leverage the established development and regulat...

Maxygen to Present at the JPMorgan 26th Annual Healthcare Conference

... improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in our pipeline is a novel Factor viia for the treatment of hemophilia. Maxygen's approach to drug discovery and development may allow us to leverage the established development and regulat...
VIIa in Biological Products

Rabbit Anti-Myosin VIIa Polyclonal Antibody, Unconjugated from Abcam

Description: Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Company:Abcam
Other Tags
(Date:9/17/2014)... The National Resident Matching Program has published ... of the relationship between unique applicant characteristics and success ... edition is based on the 2014 Main Residency Match ... school senior students and all other applicants. , ... new edition of Charting Outcomes in the Match,” said ...
(Date:9/17/2014)... 18, 2014 ADVOCATE, the premier ... announces today that they have been awarded the ... in Fort Wayne, Indiana. , ADVOCATE ... encompassing their proprietary suite of billing process software ... improves radiology billing and data quality consistency by ...
(Date:9/17/2014)... 2014 According to an August ... titled “Adverse Events Associated with Use of Enhancement ... unapproved use of Expression, a hyaluronic acid product, ... reactions including discoloration, lumps, bruising, nodules, and swelling. ... for cosmetic use include Restylane , Juvéderm, ...
(Date:9/17/2014)... 17, 2014 As kinship care continues ... who cannot live with their parents, emphasis on kinship ... to enhance services and supports for kinship caregivers and ... National Kinship Care Conference is being held this week ... best practice, policy, program and service development for kinship ...
(Date:9/17/2014)... 17, 2014 Sunday night saw ... and ushered in a new national spokesperson for ... America Organization’s official national platform, Children’s Miracle ... newest National Goodwill Ambassador. , Kazantsev’s year in ... Network Hospitals across the U.S., visiting with patients ...
Breaking Medicine News(10 mins):Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 2Health News:ADVOCATE Wins Radiology Billing Agreements with Fort Wayne Radiology 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 2Health News:Miss America 2015 Kira Kazantsev Takes On Role as Children’s Miracle Network Hospitals National Goodwill Ambassador 3
(Date:9/16/2014)... at the Columbia Center for Children,s Environmental Health at ... to demonstrate an association between childhood asthma and prenatal ... of household products. Results appear online in the journal ... to mothers exposed during pregnancy to higher levels of ... had a 72 percent and 78 percent increase in ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
(Date:9/16/2014)... EUGENE, Ore. -- Each tree species has its own ... researchers and colleagues from other institutions who studied the ... growing on a Panamanian island. , "This study demonstrates ... plant families and with different ecological strategies possess very ... Steven W. Kembel, a former postdoctoral researcher in the ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Microbiome research shows each tree species has a unique bacterial identity 2
Other Contents